[Dibutyryl cyclic adenosine monophosphate (DBc-AMP) in the treatment of recurrent malignant gliomas--report of 7 patients].
It has been demonstrated, by experiments, that DBc-AMP can induce biochemical and morphological changes in cultured glioma cells. In this paper, seven recurrent malignant glioma patients, who had received operation, radiotherapy and chemotherapy, were treated with DBc-AMP by injecting into the tumor feeding artery in 1 patient and directly into the tumor cavities in 6 patients. The results showed that although no improvement of symptoms was observed except the case by intraarterial injection, the IgG and IgA levels were elevated and tumor volume was reduced as shown by enhancement CT scan in 4 patients. It suggests that this method be a better adjuvant therapy for recurrent malignant gliomas.
Zhu
F Q
FQ
First Hospital, Suzhou Medical College.
Du
Z W
ZW
Bao
Y D
YD
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy*; D003994:Bucladesine / Q000008:administration & dosage* / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
D003994:Bucladesine